Objective To explore clinical effect of integrative medical therapy on infantile bronchiolitis. Methods 96 infants with bronchiolitis were randomly divided into a treatment group and a control group. The treatment group was treated with integrated traditional Chinese and western medicine, and the control group was treated with western medicine exclusively. Results The disappearance time for symptoms and signs in the treatment group was shorter than that of the control group. The hospitalized time (or time for observation of outpatient infusion) of the treatment group was also shorter than that of the control group (P＜0.05). The cure rate was 78.0% and the total effective rate was 96.0%% in the treatment group. However, the cure rate was 52.2% and the total effective rate was 69.6% in the control group, which had a significant difference in the two groups (P＜0.05). Conclusion Integrated traditional Chinese and western medicine can obviously shorten course of disease and hospitalized time, and also improve the curative effect of infantile bronchiolitis.

Hepatotoxicity is a common side effect for patients treated with gefitinib, but the related pathogenesis is unclear and lacks effective predictor and management strategies. A multi-omics approach integrating pharmacometabolomics, pharmacokinetics and pharmacogenomics was employed in non-small cell lung cancer patients to identify the effective predictor for gefitinib-induced hepatotoxicity and explore optional therapy substitution. Here, we found that patients with rs4946935 AA, located in Forkhead Box O3 (FOXO3) which is a well-known autophagic regulator, had a higher risk of hepatotoxicity than those with the GA or GG variant (OR = 18.020, 95%CI = 2.473 to 459.1784, P = 0.018) in a gefitinib-concentration dependent pattern. Furthermore, functional experiments identified that rs4946935_A impaired the expression of FOXO3 by inhibiting the promotor activity, increasing the threshold of autophagy initiation and inhibiting the autophagic activity which contributed to gefitinib-induced liver injury. In contrast, erlotinib-induced liver injury was independent on the variant and expression levels of FOXO3. This study reveals that FOXO3 mutation, leading to autophagic imbalance, plays important role in gefitinib-induced hepatotoxicity, especially for patients with high concentration of gefitinib. In conclusion, FOXO3 mutation is an effective predictor and erlotinib might be an appropriately and well-tolerated treatment option for patients carrying rs4946935 AA.